Experimental Medicine Unit studies at BRI

Dr. Greenbaum works with the Experimental Medicine Unit (EMU) at BRI to understand the biology behind experimental therapies. Most of these studies focus on type 1 diabetes (T1D). Some of the research projects our group has investigated in collaboration with the EMU include:

  • Siltuximab and Tocilizumab in T1D
  • AIRmax as a measure of functional beta cell mass in at-risk individuals for T1D
  • Defining early markers of response to Abatacept in new onset T1D
  • Kinetics of immune cell turnover
  • Longitudinal evaluation of immune biomarkers in T1D, T2D